Show simple item record

dc.contributor.authorShiri, T
dc.contributor.authorEvans, M
dc.contributor.authorTalarico, CA
dc.contributor.authorMorgan, AR
dc.contributor.authorMussad, M
dc.contributor.authorBuck, PO
dc.contributor.authorMcEwan, P
dc.contributor.authorStrain, WD
dc.date.accessioned2021-11-29T14:28:03Z
dc.date.issued2021-10-15
dc.date.updated2021-11-29T13:49:17Z
dc.description.abstractDebate persists around the risk-benefit balance of vaccinating adolescents and children against COVID-19. Central to this debate is quantifying the contribution of adolescents and children to the transmission of SARS-CoV-2, and the potential impact of vaccinating these age groups. In this study, we present a novel SEIR mathematical disease transmission model that quantifies the impact of different vaccination strategies on population-level SARS-CoV-2 infections and clinical outcomes. The model employs both age- and time-dependent social mixing patterns to capture the impact of changes in restrictions. The model was used to assess the impact of vaccinating adolescents and children on the natural history of the COVID-19 pandemic across all age groups, using the UK as an example. The base case model demonstrates significant increases in COVID-19 disease burden in the UK following a relaxation of restrictions, if vaccines are limited to those ≥18 years and vulnerable adolescents (≥12 years). Including adolescents and children in the vaccination program could reduce overall COVID-related mortality by 57%, and reduce cases of long COVID by 75%. This study demonstrates that vaccinating adolescents and children has the potential to play a vital role in reducing SARS-CoV-2 infections, and subsequent COVID-19 morbidity and mortality, across all ages. Our results have major global public health implications and provide valuable information to inform a potential pandemic exit strategy.en_GB
dc.description.sponsorshipModerna, Inc.en_GB
dc.format.extent1180-
dc.format.mediumElectronic
dc.identifier.citationVol. 9 (10), article 1180en_GB
dc.identifier.doihttps://doi.org/10.3390/vaccines9101180
dc.identifier.urihttp://hdl.handle.net/10871/127981
dc.identifierORCID: 0000-0002-6826-418X (Strain, William David)
dc.identifierScopusID: 56602727900 | 9244119500 (Strain, William David)
dc.identifierResearcherID: Y-9858-2019 (Strain, William David)
dc.language.isoenen_GB
dc.publisherMDPIen_GB
dc.relation.urlhttps://www.ncbi.nlm.nih.gov/pubmed/34696288en_GB
dc.rights© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).en_GB
dc.subjectCOVID-19en_GB
dc.subjectSARS-CoV-2en_GB
dc.subjectadolescenten_GB
dc.subjectcoronavirusen_GB
dc.subjectdisease transmission modelen_GB
dc.subjectvaccinationen_GB
dc.titleVaccinating Adolescents and Children Significantly Reduces COVID-19 Morbidity and Mortality across All Ages: A Population-Based Modeling Study Using the UK as an Exampleen_GB
dc.typeArticleen_GB
dc.date.available2021-11-29T14:28:03Z
dc.identifier.issn2076-393X
exeter.article-numberARTN 1180
exeter.place-of-publicationSwitzerland
dc.descriptionThis is the final version. Available on open access from MDPI via the DOI in this recorden_GB
dc.descriptionData Availability Statement: The datasets analyzed during the current study were sourced from and are available in the original publications referenced.en_GB
dc.identifier.eissn2076-393X
dc.identifier.journalVaccinesen_GB
dc.relation.ispartofVaccines (Basel), 9(10)
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/en_GB
dcterms.dateAccepted2021-10-04
rioxxterms.versionVoRen_GB
rioxxterms.licenseref.startdate2021-10-15
rioxxterms.typeJournal Article/Reviewen_GB
refterms.dateFCD2021-11-29T14:11:30Z
refterms.versionFCDVoR
refterms.dateFOA2021-11-29T14:28:19Z
refterms.panelAen_GB
refterms.dateFirstOnline2021-10-15


Files in this item

This item appears in the following Collection(s)

Show simple item record

© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Except where otherwise noted, this item's licence is described as © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).